TWA
RNAM

TCI Wealth Advisors’s Avidity Biosciences RNAM Stock Holding History

TCI Wealth Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-188
Closed -$2.89K – 1806
2023
Q1 		$2.89K Buy
+188
New +$4.14K ﹤0.01% 1867
2022
Q1 		– Sell
-159
Closed -$4K – 2419
2021
Q4 		$4K Sell
159
-130
-45% -$3.1K ﹤0.01% 1884
2021
Q3 		$7K Buy
289
+159
+122% +$3.46K ﹤0.01% 1382
2021
Q2 		$3K Hold
130
– – ﹤0.01% 1839
2021
Q1 		$3K Buy
+130
New +$3.18K ﹤0.01% 1576

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCI Wealth Advisors's RNAM Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Avidity Biosciences (RNAM) in Q2 2023, closing a stake of 188 shares — an estimated $2.89K sold.

TCI Wealth Advisors first reported a position in RNAM in Q1 2021 and held it in 5 quarters. The position peaked at $7K in Q3 2021. 143 funds tracked by Wall St. Rank hold RNAM as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Avidity Biosciences position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 188 Avidity Biosciences shares in Q2 2023, an estimated $2.89K.
  • TCI Wealth Advisors first reported a position in Avidity Biosciences in Q1 2021 and held it in 5 quarters.
  • TCI Wealth Advisors's Avidity Biosciences position peaked at $7K in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.